algeldrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4250 21645-51-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aluminum hydroxide
  • algeldrate
  • aluminum hydroxide hydrate
  • aluminium hydroxide
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
  • Molecular weight: 78.00
  • Formula: AlH3O3
  • CLOGP: -1.75
  • LIPINSKI: None
  • HAC: 3
  • HDO: 3
  • TPSA: 60.69
  • ALOGS:
  • ROTB: 0

Drug dosage:

DoseUnitRoute
5 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 61
kinase-selectivity-class ACVR2B,ACVRL1,AXL,BMX,BRAF,CDK9,EPHB4,GRK2,IRAK3,MAP2K6,MAP3K14,MAPK7,PIK3CD,PIK3CG,PRKDC,SYK,TEK,TGFBR1,ZAP70 19
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 9, 1983 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Schizoaffective disorder 813.89 21.48 154 4987 4993 90618313
Drug level increased 555.61 21.48 154 4987 27608 90595698
Electrocardiogram QT prolonged 447.20 21.48 164 4977 72292 90551014
Drug interaction 275.15 21.48 179 4962 276274 90347032
Sinus rhythm 136.66 21.48 28 5113 1358 90621948
Carbuncle 79.28 21.48 18 5123 1418 90621888
Monoclonal immunoglobulin present 67.29 21.48 17 5124 2107 90621199
Hypothalamo-pituitary disorder 66.30 21.48 17 5124 2235 90621071
Product use issue 62.78 21.48 85 5056 329834 90293472
Wrist deformity 60.18 21.48 17 5124 3221 90620085
Fibrosis 53.94 21.48 18 5123 5934 90617372
Overweight 50.04 21.48 17 5124 5917 90617389
Dysstasia 48.16 21.48 25 5116 25027 90598279
Purpura 47.52 21.48 21 5120 14757 90608549
Nephropathy 42.71 21.48 17 5124 9218 90614088
Dyslipidaemia 41.22 21.48 17 5124 10090 90613216
Renal cyst 40.34 21.48 18 5123 12932 90610374
Body height decreased 38.48 21.48 17 5124 11932 90611374
Polyglandular disorder 36.89 21.48 7 5134 227 90623079
Movement disorder 34.15 21.48 21 5120 28998 90594308
Vertebral lateral recess stenosis 34.04 21.48 7 5134 345 90622961
Osteoarthropathy 33.73 21.48 7 5134 361 90622945
Ligamentum flavum hypertrophy 33.56 21.48 7 5134 370 90622936
Bone density decreased 32.45 21.48 17 5124 17328 90605978
Anaemia folate deficiency 30.98 21.48 7 5134 539 90622767
Acute myocardial infarction 30.61 21.48 21 5120 34869 90588437
Hepatic steatosis 27.24 21.48 20 5121 36925 90586381
Endocrine disorder 27.05 21.48 7 5134 953 90622353
Cholelithiasis 27.03 21.48 23 5118 52483 90570823
Hypoparathyroidism 26.76 21.48 7 5134 994 90622312
Chronic hepatitis 25.83 21.48 7 5134 1138 90622168
Toe operation 25.69 21.48 7 5134 1161 90622145
Coma scale abnormal 24.78 21.48 10 5131 5616 90617690
Agitation 24.04 21.48 24 5117 67074 90556232
Morbid thoughts 23.71 21.48 6 5135 748 90622558
Hypercapnia 23.12 21.48 10 5131 6667 90616639
Limb injury 23.10 21.48 17 5124 31491 90591815
Skin disorder 22.93 21.48 18 5123 36688 90586618
Finger deformity 22.45 21.48 17 5124 32880 90590426
Drug ineffective 21.90 21.48 28 5113 1384270 89239036
Vitiligo 21.61 21.48 7 5134 2103 90621203

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperphosphataemia 89.53 22.19 39 4901 12965 42603430
Myasthenia gravis 81.47 22.19 39 4901 16098 42600297
Appendicolith 78.69 22.19 36 4904 13420 42602975
Appendicitis 72.44 22.19 39 4901 20574 42595821
Blood phosphorus increased 68.52 22.19 32 4908 12493 42603902
Blood uric acid increased 64.85 22.19 33 4907 15514 42600881
Iron deficiency 62.81 22.19 29 4911 11032 42605363
Stress 62.46 22.19 47 4893 44165 42572230
Ventricular fibrillation 61.17 22.19 40 4900 30083 42586312
Neuralgia 59.39 22.19 37 4903 25610 42590785
Hypophosphataemia 58.27 22.19 34 4906 20911 42595484
Bacterial infection 56.55 22.19 37 4903 27842 42588553
Cardiogenic shock 52.81 22.19 39 4901 35601 42580794
Incorrect route of product administration 51.12 22.19 33 4907 24272 42592123
Blood cholesterol increased 50.63 22.19 34 4906 26707 42589688
Drug therapy 50.05 22.19 21 4919 6359 42610036
Analgesic therapy 49.60 22.19 21 4919 6503 42609892
Dry mouth 46.79 22.19 38 4902 39841 42576554
Sleep disorder therapy 45.24 22.19 20 4920 6874 42609521
Abdominal distension 44.63 22.19 48 4892 71687 42544708
Swelling 38.19 22.19 39 4901 54846 42561549
Ascites 37.14 22.19 39 4901 56639 42559756
Intentional product misuse 36.02 22.19 40 4900 61860 42554535
Multiple organ dysfunction syndrome 36.00 22.19 50 4890 96985 42519410
Diabetes mellitus 35.26 22.19 39 4901 60048 42556347
Thrombosis 34.36 22.19 41 4899 68470 42547925
Bacteroides infection 32.59 22.19 12 4928 2575 42613820
Mesothelioma 32.41 22.19 8 4932 437 42615958
Sleep disorder 31.34 22.19 33 4907 48062 42568333
Somnolence 29.44 22.19 56 4884 141049 42475346
Pulmonary embolism 29.44 22.19 51 4889 119561 42496834
General physical health deterioration 27.90 22.19 57 4883 151189 42465206
Catarrh 25.81 22.19 13 4927 5973 42610422
Chronic obstructive pulmonary disease 25.63 22.19 34 4906 63080 42553315
Activated partial thromboplastin time prolonged 24.89 22.19 18 4922 15885 42600510
Pneumocystis jirovecii infection 24.41 22.19 10 4930 2850 42613545
Systemic lupus erythematosus 22.96 22.19 14 4926 9310 42607085
Alcohol poisoning 22.93 22.19 13 4927 7561 42608834
Burns second degree 22.71 22.19 12 4928 6084 42610311

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperphosphataemia 96.84 18.88 39 8327 16342 110564591
Appendicolith 91.44 18.88 36 8330 14219 110566714
Myasthenia gravis 86.60 18.88 39 8327 21472 110559461
Appendicitis 76.20 18.88 39 8327 28425 110552508
Blood phosphorus increased 73.41 18.88 32 8334 16308 110564625
Blood uric acid increased 71.00 18.88 34 8332 21495 110559438
Carbuncle 68.67 18.88 17 8349 1450 110579483
Ventricular fibrillation 67.75 18.88 41 8325 41272 110539661
Iron deficiency 66.52 18.88 31 8335 18445 110562488
Diabetes mellitus 66.13 18.88 57 8309 99324 110481609
Monoclonal immunoglobulin present 59.42 18.88 17 8349 2523 110578410
Hypothalamo-pituitary disorder 57.50 18.88 17 8349 2829 110578104
Hypophosphataemia 57.17 18.88 34 8332 33148 110547785
Analgesic therapy 56.03 18.88 21 8345 7263 110573670
Drug therapy 56.01 18.88 21 8345 7270 110573663
Wrist deformity 55.60 18.88 17 8349 3172 110577761
Bacterial infection 53.99 18.88 37 8329 45999 110534934
Neuralgia 52.26 18.88 37 8329 48441 110532492
Sleep disorder therapy 51.92 18.88 20 8346 7451 110573482
Chronic obstructive pulmonary disease 50.22 18.88 51 8315 109107 110471826
Cardiogenic shock 48.88 18.88 38 8328 57300 110523633
Stress 44.46 18.88 47 8319 105301 110475632
Overweight 43.83 18.88 17 8349 6447 110574486
Multiple organ dysfunction syndrome 41.21 18.88 54 8312 151656 110429277
Fibrosis 41.08 18.88 17 8349 7625 110573308
Purpura 39.45 18.88 24 8342 24364 110556569
Hyponatraemia 38.13 18.88 63 8303 217590 110363343
Ascites 36.69 18.88 40 8326 92768 110488165
Bacteroides infection 36.17 18.88 12 8354 2907 110578026
Pulmonary embolism 36.13 18.88 61 8305 214413 110366520
Body height decreased 35.79 18.88 17 8349 10546 110570387
Incorrect route of product administration 35.20 18.88 33 8333 64028 110516905
Nephropathy 34.73 18.88 18 8348 13449 110567484
Acute myocardial infarction 34.68 18.88 37 8329 83740 110497193
Polyglandular disorder 34.53 18.88 7 8359 239 110580694
Vertebral lateral recess stenosis 32.03 18.88 7 8359 345 110580588
Ligamentum flavum hypertrophy 31.59 18.88 7 8359 368 110580565
Thrombosis 31.57 18.88 40 8326 108622 110472311
Osteoarthropathy 31.52 18.88 7 8359 372 110580561
Abdominal distension 31.09 18.88 51 8315 175052 110405881
Dysstasia 30.61 18.88 23 8343 32963 110547970
Violence-related symptom 29.70 18.88 8 8358 951 110579982
Renal cyst 29.69 18.88 18 8348 18154 110562779
Dyslipidaemia 29.18 18.88 17 8349 15948 110564985
Bone density decreased 29.10 18.88 17 8349 16025 110564908
Activated partial thromboplastin time prolonged 28.66 18.88 19 8347 22349 110558584
Catarrh 28.57 18.88 13 8353 7322 110573611
Intentional product misuse 28.16 18.88 42 8324 132862 110448071
Anaemia folate deficiency 27.24 18.88 7 8359 694 110580239
Somnolence 26.56 18.88 65 8301 297384 110283549
Alcohol poisoning 26.00 18.88 13 8353 9007 110571926
Limb injury 25.85 18.88 22 8344 37614 110543319
Burns second degree 24.85 18.88 12 8354 7721 110573212
Toe operation 24.68 18.88 7 8359 1007 110579926
End stage renal disease 24.56 18.88 17 8349 21456 110559477
Movement disorder 24.44 18.88 21 8345 36383 110544550
Pneumocystis jirovecii infection 24.37 18.88 10 8356 4390 110576543
General physical health deterioration 24.27 18.88 79 8287 425216 110155717
Endocrine disorder 23.96 18.88 7 8359 1117 110579816
Steroid dependence 23.81 18.88 12 8354 8457 110572476
Cerebrovascular accident 23.45 18.88 46 8320 181238 110399695
Hypoparathyroidism 21.84 18.88 7 8359 1523 110579410
Weight increased 21.72 18.88 3 8363 419641 110161292
Stenotrophomonas infection 21.61 18.88 10 8356 5848 110575085
Aortic stenosis 21.50 18.88 13 8353 13046 110567887
Mesothelioma 20.90 18.88 5 8361 369 110580564
Chronic hepatitis 20.83 18.88 7 8359 1765 110579168
Morbid thoughts 20.82 18.88 6 8360 913 110580020
Hypopnoea 20.49 18.88 12 8354 11368 110569565
Pneumonia cytomegaloviral 19.98 18.88 10 8356 6944 110573989
Cholelithiasis 19.46 18.88 24 8342 63398 110517535
Gingival pain 19.28 18.88 13 8353 15723 110565210

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02AB01 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
ANTACIDS
Aluminium compounds
ATC A02AB02 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
ANTACIDS
Aluminium compounds
MeSH PA D000276 Adjuvants, Immunologic
MeSH PA D000863 Antacids
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D007155 Immunologic Factors
CHEBI has role CHEBI:65265 antacid
CHEBI has role CHEBI:79314 flame retardant
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:70868 antileishmanial agent

Related Drugs by ATC class:

A02AB Aluminium compounds 5 drugs
aloglutamolaluminium acetoacetatealuminium glycinatealuminium phosphatecarbaldrate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Peptic ulcer indication 13200003 DOID:750
Heartburn indication 16331000
Duodenal ulcer disease indication 51868009 DOID:1724
Indigestion indication 162031009
Gastroesophageal reflux disease indication 235595009 DOID:8534
Gastric ulcer indication 397825006 DOID:10808
Gastric Hypersecretory Conditions indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.51 acidic
pKa2 4.99 acidic
pKa3 5.47 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018607 VUID
N0000146920 NUI
D02807 KEGG_DRUG
1330-44-5 SECONDARY_CAS_RN
4017984 VANDF
4018607 VANDF
4019302 VANDF
C0002371 UMLSCUI
CHEBI:755909 CHEBI
CHEMBL3833310 ChEMBL_ID
CHEMBL1200706 ChEMBL_ID
D000536 MESH_DESCRIPTOR_UI
1945 INN_ID
03J11K103C UNII
22721319 PUBCHEM_CID
DB06723 DRUGBANK_ID
612 RXNORM
4159 MMSL
5582 MMSL
7537 MMSL
d00978 MMSL
001123 NDDF
007943 NDDF
273944007 SNOMEDCT_US
725733004 SNOMEDCT_US
768557001 SNOMEDCT_US
80399002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mag-AL Liquid HUMAN OTC DRUG LABEL 2 0121-1760 SUSPENSION 200 mg ORAL OTC Monograph Drug 14 sections
Mag-AL Plus HUMAN OTC DRUG LABEL 3 0121-1761 SUSPENSION 200 mg ORAL OTC Monograph Drug 14 sections
Mag-AL PlusXS HUMAN OTC DRUG LABEL 3 0121-1762 SUSPENSION 400 mg ORAL OTC Monograph Drug 15 sections
GAVISCON HUMAN OTC DRUG LABEL 2 0135-0094 LIQUID 95 mg ORAL OTC Monograph Drug 13 sections
GAVISCON HUMAN OTC DRUG LABEL 2 0135-0095 LIQUID 254 mg ORAL OTC Monograph Drug 13 sections
GavisconExtra Strength HUMAN OTC DRUG LABEL 2 0135-0098 TABLET, CHEWABLE 160 mg ORAL OTC Monograph Drug 12 sections
GavisconExtra Strength HUMAN OTC DRUG LABEL 2 0135-0430 TABLET, CHEWABLE 160 mg ORAL OTC Monograph Drug 12 sections
GAVISCON HUMAN OTC DRUG LABEL 2 0135-0574 LIQUID 254 mg ORAL OTC Monograph Drug 13 sections
FAST ACTING Heartburn Relief HUMAN OTC DRUG LABEL 2 0363-1155 TABLET, CHEWABLE 160 mg ORAL OTC Monograph Drug 12 sections
ADVANCED REGULAR STRENGTH ANTACID HUMAN OTC DRUG LABEL 3 0363-1639 SUSPENSION 200 mg ORAL OTC Monograph Drug 10 sections
MAXIMUM STRENGTH ANTACID ANTIGAS HUMAN OTC DRUG LABEL 3 0363-1691 SUSPENSION 400 mg ORAL OTC Monograph Drug 10 sections
REGULAR STRENGTH ANTACID ANTIGAS HUMAN OTC DRUG LABEL 3 0363-2628 SUSPENSION 200 mg ORAL OTC Monograph Drug 10 sections
Walgreens Fast Acting Heartburn Relief Extra Strength HUMAN OTC DRUG LABEL 2 0363-7630 LIQUID 254 mg ORAL OTC Monograph Drug 13 sections
ALMACONE DOUBLE STRENGTH HUMAN OTC DRUG LABEL 3 0536-0015 SUSPENSION 400 mg ORAL OTC Monograph Drug 10 sections
Aluminum Hydroxide HUMAN OTC DRUG LABEL 1 0536-0091 LIQUID 320 mg ORAL OTC Monograph Drug 10 sections
Antacid Human OTC Drug Label 3 0536-1293 LIQUID 400 mg ORAL OTC Monograph Drug 12 sections
REGULAR STRENGTH ANTACID/ANTIGAS HUMAN OTC DRUG LABEL 3 0536-1317 SUSPENSION 400 mg ORAL OTC Monograph Drug 10 sections
Acid Gone Antacid Extra Strength HUMAN OTC DRUG LABEL 2 0904-5365 TABLET, CHEWABLE 160 mg ORAL OTC Monograph Drug 12 sections
MINTOX MAXIMUM STRENGTH HUMAN OTC DRUG LABEL 3 0904-5725 SUSPENSION 400 mg ORAL OTC Monograph Drug 9 sections
Mintox Plus Tabs HUMAN OTC DRUG LABEL 3 0904-6700 TABLET, CHEWABLE 200 mg ORAL OTC Monograph Drug 14 sections
Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone HUMAN OTC DRUG LABEL 3 0904-7557 SUSPENSION 1200 mg ORAL OTC Monograph Drug 13 sections
ACID GONE ANTACID HUMAN OTC DRUG LABEL 2 0904-7727 LIQUID 95 mg ORAL OTC Monograph Drug 10 sections
Extra StrengthAntacid HUMAN OTC DRUG LABEL 2 11673-814 TABLET, CHEWABLE 160 mg ORAL OTC Monograph Drug 12 sections
Extra StrengthAntacid HUMAN OTC DRUG LABEL 2 11673-814 TABLET, CHEWABLE 160 mg ORAL OTC Monograph Drug 12 sections
Rite Aid Extra Strength HUMAN OTC DRUG LABEL 2 11822-1050 TABLET, CHEWABLE 160 mg ORAL OTC Monograph Drug 12 sections
Rite Aid Extra Strength HUMAN OTC DRUG LABEL 2 11822-1051 TABLET, CHEWABLE 160 mg ORAL OTC Monograph Drug 12 sections
REGULAR STRENGTH ANTACID AND GAS RELIEF HUMAN OTC DRUG LABEL 3 11822-3324 SUSPENSION 200 mg ORAL OTC Monograph Drug 10 sections
MAXIMUM STRENGTH ANTACID AND GAS RELIEF HUMAN OTC DRUG LABEL 3 11822-3727 SUSPENSION 400 mg ORAL OTC Monograph Drug 10 sections
MAXIMUM STRENGTH ANTACID AND ANTIGAS HUMAN OTC DRUG LABEL 3 11822-5742 LIQUID 400 mg ORAL OTC Monograph Drug 10 sections
Aluminum Hydroxide HUMAN OTC DRUG LABEL 1 17856-0091 LIQUID 320 mg ORAL OTC Monograph Drug 10 sections